hVIVO's 2025 Final Results: Strategic Shifts Amid Financial Challenges

hVIVO 2025 results: a reset year building a broader clinical engine

hVIVO has posted a tough set of numbers for 2025 as Human Challenge Trial (HCT) demand wobbled and the Group deliberately pivoted to a more diversified, integrated model. Revenue fell, margins compressed and cash stepped down, but management spent the year stitching together a fuller early clinical development platform with two acquisitions, a new multi-site delivery model and fresh laboratory capability.

For retail investors, this is a classic transition story. The financials reflect the hit from cancelled HCTs; the strategy is about reducing concentration risk and widening the addressable market across Consulting, Clinical Trials, Human Challenge Trials and Laboratories.

Key figures investors should know

Metric	2025	2024	Comment
Revenue	£46.8 million	£62.7 million	Impacted by HCT cancellations
Adjusted EBITDA	£1.4 million	£16.4 million	Margin 3.0% vs 26.2%
Operating (loss)/profit	£(4.6) million	£12.9 million	Includes £1.4 million exceptional items
Basic adjusted EPS	(0.41)p	1.69p	Reflects lower activity and acquisition amortisation
Cash at 31 Dec	£14.3 million	£44.2 million	Acquisitions and lower HCT activity drove outflows
Weighted orderbook	£30 million	£43.5 million (restated)	Shift to smaller, repeatable contracts; bolstered post period by Traws
Other operating income	£2.9 million	£3.5 million	Mainly R&D tax credits

Note: Adjusted EBITDA is before one-off acquisition and reorganisation costs.

What drove the downturn in 2025?

Management is plain about the cause: a difficult macro environment, particularly in the US, which led to significant HCT cancellations and fewer new contract awards. That squeezed utilisation and margins in the core challenge business.

The geographic mix underscores the shift. Europe revenue rose to £22.6 million (2024: £17.4 million), helped by acquisitions, while North America more than halved to £18.0 million (2024: £43.1 million). Customer concentration eased too: the top three customers represented 14%, 11% and 11% of revenue, versus as high as 31% for a single customer in 2024.

The strategic reset: four service lines and real assets

Two deals broadened the platform early in the year. hVIVO bought two Clinical Research Units from CRS for €10.0 million and acquired Cryostore for £3.2 million. Together they extend hVIVO into early-phase trials, biobanking and temperature-controlled storage, and deepen therapeutic reach into cardiometabolic, immunology and renal impairment studies.

• Consulting – early scientific, regulatory and development strategy to set up trials right first time.
• Clinical Trials – owned Phase I/II CRO capability and Phase II/III site services in the UK and Germany.
• Human Challenge Trials – still the crown jewel, delivered from the London quarantine unit.
• Laboratories – virology, immunology, biomarker analysis, plus biobanking through Cryostore.

The integration work was executed to plan. CRS generated cash in Q4 2025 and is expected to be earnings accretive in 2026. A unified brand was unveiled post period, with Venn Life Sciences, CRS and Cryostore all operating under the hVIVO banner to simplify the go-to-market.

Operational nuggets: cross-selling, labs and model leadership

• First multi-site contracts were signed, leveraging the now wider UK and German footprint.
• Record Phase III activity was delivered by Clinical Site Services, with Germany becoming a preferred provider for multiple mid-sized pharma clients.
• The bacterial laboratory at Canary Wharf was completed, enabling future bacterial HCTs.
• The world’s only contemporary-strain hMPV challenge model was validated for vaccine and antiviral trials.
• The Cidara partnership showcased the end-to-end approach, supporting CD388 from HCT proof-of-concept through Phase IIb to Phase III site and central lab roles, ahead of Cidara’s approximately $9.2 billion acquisition by MSD.

Cash, dividends and orderbook: reading the signals

Cash fell to £14.3 million as acquisitions completed and core HCT activity dipped. Operating cash outflow was £14.4 million, with a further £10.9 million of investing cash outflow and £4.6 million from financing, including £1.4 million of dividends relating to 2024. With liquidity monitored closely, the Board is not paying a dividend for 2025, prioritising reinvestment and balance sheet rebuild.

The contracted orderbook stood at £30 million at year end. Importantly, reporting has been tightened: only fully signed Clinical Trial Agreements will be announced and included going forward, rather than earlier Start-Up Agreements that carry higher cancellation risk. Management says the post-period contract with Traws Pharma has significantly bolstered the book.

2026 outlook: measured growth, H2-weighted

Guidance is for high single-digit revenue growth in 2026, weighted to the second half. The sales pipeline is broadening across all four service lines, with improving conversion at CRS and more cross-sell between Site Services and Consulting.

Potential catalysts include a pivotal Phase III HCT with ILiAD Biotechnologies, which hVIVO is finalising, and ongoing demand for influenza HCTs, evidenced by the Traws Pharma contract. Growth initiatives are clear: expand cardiometabolic specialism, broaden respiratory into asthma and COPD beyond viral disease, and scale lab services as a standalone revenue engine.

My take: why this matters and how to think about the shares

This is a reset year where the P&L took the pain, but the operating model now looks more resilient. The shift away from heavy reliance on a handful of HCTs towards a mix of smaller, repeatable contracts should smooth revenues and improve visibility. The owned infrastructure across sites and labs is a competitive advantage that many mid-sized peers lack.

What looks positive

• Diversification is real: four integrated service lines, new therapeutic focus areas and multi-site capability.
• CRS is already cash generative and expected to be earnings accretive in 2026.
• Orderbook quality should improve with the move to count only fully executed CTAs.
• Unique scientific assets, such as the hMPV model and the large quarantine facility, support pricing power and differentiation.

What to keep an eye on

• Cash buffer is smaller at £14.3 million. Delivery against H2-weighted guidance and working capital discipline will matter.
• Conversion of the diversified pipeline into signed CTAs, not just proposals.
• Margin rebuild from 3.0% adjusted EBITDA in 2025 as utilisation improves and cross-selling scales.
• Timing and size of the ILiAD Phase III HCT and any additional multi-site wins.

Bottom line

2025 was tough on the numbers, but constructive on strategy. If the broader platform now converts into steadier bookings and the acquired units keep contributing, hVIVO has multiple paths to restore growth and margins in 2026 and beyond. Execution through H1, and the flow of fully signed contracts, will be the proof points to watch.